Phase i dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer
Amita Patnaik, Kyriakos P. Papadopoulos, Anthony W. Tolcher, Muralidhar Beeram, Saïk Urien, Larry J. Schaaf, Sanaa Tahiri, Tanios Bekaii-Saab, François M. Lokiec, Keyvan Rezaï, Aby Buchbinder
Dive into the research topics of 'Phase i dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer'. Together they form a unique fingerprint.